Abstract: The invention encompasses diagnosis and prognosis in the context of heart or renal failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The invention also relates to methods of assigning an increased likelihood that a subject having AKI is susceptible to AKI progression. The invention relates in part to assigning a diagnosis of heart and/or renal failure, and/or an outcome risk (e.g., worsening cardiac and/or renal function or a mortality risk) to a subject based, at least in part, on the result(s) obtained from an assay that detects WAP four-disulfide core domain protein 2 performed on a body fluid sample obtained from a subject.

Abstract: The present invention relates in part to diagnosing the occurrence of heart failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The present invention further relates in part to assigning an outcome risk (e.g., worsening cardiac function or a mortality risk, a risk of rehospitalization) to a subject. The methods comprise performing one or more assays that detect one or more biomarkers selected from the group consisting of WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 performed on a body fluid sample obtained from a subject, and assigning diagnosis or risk based, at least in part, on the result(s) obtained thereby.

Abstract: The present invention relates in part to diagnosing the occurrence of heart failure, particularly in subjects who exhibit a normal body fluid level of a natriuretic peptide. The present invention further relates in part to assigning an outcome risk (e.g., worsening cardiac function or a mortality risk, a risk of rehospitalization) to a subject. The methods comprise performing one or more assays that detect one or more biomarkers selected from the group consisting of WAP4C, ESAM, LTBR, Mesothelin, and Syndecan-1 performed on a body fluid sample obtained from a subject, and assigning diagnosis or risk based, at least in part, on the result(s) obtained thereby.

Abstract: A lysis chamber of an assay device capable of producing lysis of cells in a sample fluid such as whole blood, said chamber comprising a surface which contacts the sample fluid when the sample fluid is placed into the assay device; and a lytic material immobilized on the surface, whereby cells of the sample fluid are lysed when they contact the lytic material. The chamber can delimit a capillary space, and lytic material can be saponin or a detergent. Methods employing devices comprising such chambers can assay for whole blood amounts of cyclosporin or hemoglobin A1c.